The acquisition brings FB102, a first-in-class anti-CD122 antibody, into the immunology pipeline, supporting growth ambitions and expanding the portfolio into large autoimmune indications like vitiligo and celiac disease. The $2.2B cash deal leverages proven development and commercialization strategies to maximize FB102's impact.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.